chrisvoncsefalvay/vaers-outcomes huggingface dataset:
COVID-19 treatment; COVID-19 treatment; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 72-year-old male patient received BNT162b2 (BNT162B2), on 09Mar2021 at 03:00 as dose 1, single (Lot number: EN6198), in left arm, in 2021 as dose 2, single (Batch/Lot number: unknown), in left arm, on 07Oct2021 at 02:00 as dose 3 (booster), single (Lot number: FC3180), in left arm and on 06Apr2022 at 10:15 as dose 4 (booster), single (Lot number: FJ4991) at the age of 71 years, in left arm for covid-19 immunisation. The patient's relevant medical history included: "COPD" (unspecified if ongoing), notes: COPD; "CLL" (unspecified if ongoing), notes: CLL. There were no concomitant medications. The following information was reported: COVID-19 (medically significant) with onset 2022, outcome "not recovered", DRUG INEFFECTIVE (medically significant) with onset 2022, outcome "unknown" and all described as "COVID-19 treatment". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (Jun2022) positive, notes: I took Paxlovid and after 5 day quarantine I still tested positive for COVID; (Jun2022) Positive, notes: After 5 more days I still tested positive. Therapeutic measures were taken as a result of covid-19, drug ineffective.   Clinical course: I took Paxlovid and after 5 day quarantine I still tested positive for COVID. After 5 more days I still tested positive. New symptoms came on day11. No Known allergies reported. No other medication in 2 weeks.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
Within a day and a half swelling of the face, especially around eyes. Rashes on face at brow and cheeks with flaking skin, in addition to hive on forearms. The following morning, today, it has become much more severe.
had hives over much of her body; This spontaneous case was reported by a consumer and describes the occurrence of URTICARIA (had hives over much of her body) in a 78-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. unknown) for COVID-19 vaccination.     No Medical History information was reported.    On 09-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 10-Feb-2021, the patient experienced URTICARIA (had hives over much of her body). At the time of the report, URTICARIA (had hives over much of her body) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medications were reported.  No treatment information was reported.
Pfizer-BioNTech COVID-19 Vaccine   headache 5 minutes after IM injection of dose 1, did not recover after 15 minutes of observation.
This spontaneous report as received from a Registered Nurse refers to twin patients age unknown and gender unknown  which were vaccinated with (Oka/Merck) VARIVAX. On 20-JUN-2014, the patient was vaccinated with (Oka/Merck) VARIVAX, subcutaneous. This is the second dose in the series. On 20-JUN-2014, the patient received VARIVAX that was exposed to a maximum of 17.2 Fahrenheit for cumulative 41.5 hours (supported). The outcome of receiving VARVIAX that was exposed to a maximum of 17.2 Fahrenheit for cumulative 41.5 hours is unknown. Additional information is not expected. This case is linked to 1407USA012109 due to twin patients who were vaccinated on the same date 20-JUN-2014.
Irregular heartbeat , severe & frequent premature atrial contractions, heart racing uncontrollably, blood pressure spikes
PAIN AND EXTENSIVE SWELLING, WARMTH AND ERYTHEMA WITH TENDERNESS EXTENDING TO PROX FOREARM COVERED FOR POSSIBLE CELLULITIS AND IMPROVEMENT AFTER PARENTERAL AND ORAL ANTIBIOTICS GIVEN.
A 36 yr old female pt with a medical history of no known allergies, although a seasonal intake of Allegra was reported, no medical conditions and no illness at the time of the vaccination experienced warmth and parasthesia in her right side of the hip, back and stomach i.e. approximately 30 minutes following the IM, deltoid administration of the influenza vaccine (Fluzone) on an unspecified date.  The pt visited a doctor following the event. It was reported that the vaccine administered approx three weeks ago from the time of the report. The pt was going for an MRI and she had not recovered at the time of the report.
11FEB93 swollen cervical glands; sore throat, fever-h/a; 12FEB93 rash started on trunk then to extremities; 13FEB93 joint pain hisp severe-knees; 15FEB92 rash began to disappear; 17FEB92 rash gone fever gone, joint pain gone;
Patient returned to our office on 4/14/10 with complaints of swelling to her face and a rash on her neck that started after she got home the day she received the vaccine.
t104 R wen to hosp ER dx febrile reaction to HIB r/o OM (rt) pt given amoxicillin;
Employee stated that at approximately 1900 on 17 Aug 15 she developed a rash to her chest area that was itching. It has since spread to her back on 8-18-15. It is a fine, raised red rash.
Patient received vaccine after beyond use date of  07/29/2022 (30 day freezer to fridge dating). Patient contacted, but cannot be reached.
Pain at injection site; pain in rib cage and thoracic spine; pain in rib cage and thoracic spine; stiffness; chills; rash on my face and injection site; rash on my face and injection site; blurred vision/cloudy; digestive issues; headache; This is a spontaneous report from a contactable consumer (patient). A 42-year-old non-pregnant female patient received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, lot number: EW0171), via an unspecified route of administration, on 23May2021 at 12:30 (at the age of 42-years) as single dose in left arm, for covid-19 immunization. Medical history included: allergies, meningitis, low back pain, SI joint disfunction, IBS and known allergies: Sulfa drugs, soaps, detergents, and other household products. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient's concomitant medications included: ibuprofen, multivitamin, antioxidants, leaky gut r. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient was not pregnant at the time of vaccination. On 23May2021 at 22:30, the patient experienced pain at injection site, pain in rib cage and thoracic spine, stiffness, chills, rash on my face and injection site, blurred vision, cloudy, digestive issues and headache. The patient did not receive any treatment for the events. Since the vaccination, the patient has not been tested for COVID-19. The outcome of events was not recovered.
Suffer a stroke a few weeks after the vaccine; 42 days pasted since his first dose; A spontaneous report was received from a son, concerning a  92 year old male patient, his father, who received Moderna's COVID-19 vaccine (mRNA-1273) and experienced stroke a few weeks after the vaccine and it was known that missed the second date, 42 days passed since the first dose.  The patient's medical history was not provided. No relevant concomitant medications were reported.  On 22 Jan 2021, prior to the onset of the events the patient received their first of two planned doses of mRNA-1273 (batch number: unknown) intramuscularly for prophylaxis of COVID-19 infection.  On an unknown date, the patient experienced a stroke and went to nursing home. Th patient had missed the second vaccine dose which was scheduled for 19-Feb-2021. It was known that 42 days have passed since the patient had the initial dose administered. No treatment information was provided.   The outcome of event, 42 days passed since his first dose was recovered.   The outcome of the event, suffer a stroke a few weeks after the vaccine, was unknown.; Reporter's Comments: This report refers to a case of 92- year-old male patient who experienced serious unexpected event of stroke a few weeks after the vaccine and missed the second date (Product dose omission issue) for mRNA-1273. Limited information regarding the event of stroke has been provided at this time. Patients medical history, onset date, clinical details and diagnostic results of the event are lacking. Further information has been requested. The event of product dose omission issue is considered not applicable.
Extreme fatigue. Low Blood Pressure. Loss of appetite. Extreme sensitivity at vaccination site, whenever my immune system is compromised. Loss of weight.
R upper arm localized, redness, swelling, tenderness, warmth developed within 24 hrs of vaccination, improving by 72 hours after vaccination.
I am a 57 years old caucasian female. I entered menopause in early 2012, my ast menstral period was January 2016. My menopause symptoms were mild, some hot flashes, insomnia, and foggy brain. I had no depression or crying episodes. I went gluten free in May of 2012 and my menopause symptoms disappeared completely within a few months. A few days after my first COVID-19 vaccine the menopause symptons returned stronger, and with them came a sense that my heart was breaking and an overwhelming sense that I was about to burst into tears. The 2nd dose of the COVID-19 vaccine increased these symptoms. As of today, 8/7/2021 the only sympton that has disappeared are the hot flashes. The others are getting worse.
Patient's wife called and said he had developed a rash this morning on his upper leg , hip, and back.
This 63 year old female consumer received 0.5mL of Diphtheria/Tetanus Toxoids/Acellular Pertussis Vaccine (DTaP) at a local health center on 28Jun2010. On 28Jun2010, the patient left the clinic having no symptoms of any kind. The patient's relevant medical history includes no previous allergic reaction to DTaP. The patient's relevant concomitant medications and past drug history are unknown. On 09Jul2010, the patient arrived to the clinic and presented to a health care partner with what looked as an allergic reaction that affected dermatologic system. The consumer was immediately referred to a triage nurse. The consumer was treated with Bactrim to help the patient's reaction to the vaccine and Silvadene ointment applied and bacitracin given to the patient for the use at home if her symptoms worsen. No additional laboratory testing was performed and no rescue drugs were used. The patient did not return to the clinic with complaints from the reaction after Silvadene was applied and after treatment with bacitracin and Bactrim. The outcome of the allergic reaction is unknown.
1/5/2021 vaccine 1/6/2021 woke up 7/730 with HA. Dont get usually. Nausea was worse then usual. Body aches, chills, arm was really sore and could barely lift for 48 hours. Took tylenol; helped for 30 minutes but then came back. Gone by the evening.  7/28/2021 2nd pregnancy
a 17-year old patient received both doses of the vaccine.; This spontaneous case was reported by a health care professional and describes the occurrence of PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (a 17-year old patient received both doses of the vaccine.) in a 17-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 014C21A and 031B21A) for COVID-19 vaccination.     No Medical History information was reported.   On 01-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 29-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 29-Apr-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (a 17-year old patient received both doses of the vaccine.). At the time of the report, PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (a 17-year old patient received both doses of the vaccine.) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Action taken with mRNA-1273 in response to the events was not Applicable. No  concomitant medications reported
Information has been received from a pharmacist referring to multiple unspecified patients of unknown age and gender. The patients' medical history, concurrent condition and concomitant medication were not reported. On unknown dates, the patients were vaccinated with ZOSTAVAX (dose, route, lot# and expiration date were not reported). On unknown dates, the patients felt "itchy" at the injection site for an unknown amount of time. At the time of reporting, the outcome of the event was unknown. The relatedness between the event and ZOSTAVAX was not reported. Additional information has been requested.
The vaccine site had slight swelling after shot but had gone away about a week after, last night it began to itch, this afternoon, I looked and it was red, swollen and very itchy. I also am running a (slight) fever.
Left arm pain at injection site. Increasing and ongoing pain. Seen in EW for f/u care.
Fever 100 degrees evening of injection lethargic even warmer in later evening, felt hot at night, Notices fever comes and goes every day, Feel weak- arms hands, leg (Hasn't being checking temp. Feels like its hard to do work work or exercise (She will see an MD).
I was having a lot of running nose. I was really tired, and I had body ache. I vomited once I had diarrhea. My fever stayed below 99.5 the whole time. It lasted for 3 weeks.
2nd night after vaccine.   Over night Chest pain radiated to neck and left shoulder pain level 5 of 10 - hurts more laying down.  Hurts when moved. Hurts when inhaled.  Hurts worse when bending forward then inhaling.    Hurts more with exertion.  This morning pain level 4 of 10.  Relieved this morning by taking Pepcid and Tylenol to pain level of 2 then 0.   She has no prior history of anything like this.  If this reoccurs,  worsens or does not improves with Tylenol and Pepcid we will take her to emergency room per what our family physician suggested.
Patient was given adult formula for Hep B #1 - Hep B #2. Reporting to as per CDC recommendation.
Patient was administered Td and PNEUMOVAX 23 on 08/22/08, in different arms. Two or three days later, patient started experiencing soreness and weakness in both of her arms. Patient's arm weakness is getting worse and she is unable to hold arms above her head. The following follow up information was assessed as "serious and unexpected".  Follow up obtained on 11/05/2008: During a follow up conversation on 11/05/08, patient's doctor stated that the patient had recently been diagnosed with bilateral "frozen shoulder" and was undergoing physical therapy. The patient was seen in the clinic on 10/14/08 for a separate complaint and was noted to have persistent shoulder pain and weakness. She was given refills of NSAID and cyclobenzaprine. On 11/03/08 the patient informed the clinic that she was now receiving physical therapy for frozen shoulder. According to the doctor, the patient is unable to lift either arm above her hips. She has not been referred to neurology or orthopedics.
Dizziness, Headache, Myalgia, chills, no fever Narrative:
Headache, Myalgia, Fever, NauseaVomiting, fatigue 24 hours after 2nd dose Narrative:
Got the shot and then got shingles; Shingles very mild; This serious case was reported by a consumer via interactive digital media and described the occurrence of suspected vaccination failure in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   On an unknown date, the patient received Shingles vaccine. On an unknown date, an unknown time after receiving Shingles vaccine, the patient experienced vaccination failure (Verbatim: Got the shot and then got shingles) (serious criteria GSK medically significant) and shingles (Verbatim: Shingles very mild). The outcome of the vaccination failure was unknown and the outcome of the shingles was recovered/resolved.   It was unknown if the reporter considered the vaccination failure and shingles to be related to Shingles vaccine.     It was unknown if the company considered the vaccination failure and shingles to be related to Shingles vaccine.   Additional Information: GSK Receipt Date: 14-Mar-2023 The reporter reported the case via interactive digital media. The patient got the shot and then got shingles, but it was very mild. Shingles went away fast, not nearly as bad as it could have been. This case was considered as suspected vaccination failure as details regarding completion of primary vaccination schedule and laboratory confirmation were unknown at the time of reporting. The follow-up would not possible as no contact details were available.
his throat feels "uncomfortable; he developed a sore throat that same day; first dose of GARDASIL 9 on an unspecified date in March 2020, his second dose on an unspecified date in June 2020, and his third dose on 11/3/2020.; received the GARDASIL 9 vaccine at the age of 57; This spontaneous report as received from a 57-year-old male patient who reported on himself. There was no information about the patient's concurrent conditions, concomitant therapies or medical history provided.     On an unknown date in March 2020, at the age of 57, the patient was vaccinated with the first dose of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) (exact dose, route of administration, anatomical location, lot # and expiration date were not reported) as Human papillomavirus (HPV) prevention (product administered to patient of inappropriate age). He received his second dose on an unspecified date in June 2020 and his third dose on 03-NOV-2020 (exact dose, route of administration, anatomical location, lot # and expiration date were not reported for any of the doses); both as HPV prevention (inappropriate schedule of product administration). The patient additionally received the COVID-19 vaccine (SARS-COV-2 VACCINE); the first dose was received on an unspecified date in December 2020 and the second dose on an unspecified date in January 2021 (exact dose, route of administration, anatomical location, lot # and expiration date were not reported) for prophylaxis. On 22-MAY-2021, he engaged in intercourse with his girlfriend and he developed a sore throat that same day. The patient stated his throat felt "uncomfortable" and he wanted to receive a fourth dose of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9). On an unspecified date, he was tested for COVID-19 and the test results were negative. He wanted a "Merck Specialist" to call him back and tell him he can receive a fourth dose of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) GARDASIL 9. The outcome of the events was unknown.  The causality assessment between the events and the suspect vaccines was not provided.
severe migraine; This spontaneous case was reported by an other health care professional and describes the occurrence of MIGRAINE (severe migraine) in a 55-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 007C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 11-Jun-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 11-Jun-2021, the patient experienced MIGRAINE (severe migraine). The patient was treated with KETOROLAC for Migraine, at a dose of 1 dosage form. At the time of the report, MIGRAINE (severe migraine) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Treatment medication included Pain medication and Pseudaphed.  No concomitant medication has been reported.
This case is part of cluster of 2 cases (same reporter, same product: ADACEL, lot number C4344AB) and is linked to case number 2013-04002. Initial report received from a healthcare professional on 11 March 2013. A female patient (date of birth: not available and age at the time of vaccination not reported), had received first dose of ADACEL vaccine (batch number: C4344AB, expiry date: 06/04/2015, site of administration was not reported) intramuscularly on 07 March 2013. The patient's pre-existing physician diagnosed allergies, birth defects; medical conditions and illness at the time of vaccination were unknown. The patient's concomitant medications were not reported. On 08 March 2013 (next day of vaccination), the patient felt a knot which was painful at the injection site and had a red rash around the lump with pain in arms both direction. Corrective treatment and laboratory details were not reported. On an unspecified date, the patient had recovered from the events. List of documents held by sender was none.
Within 24 hours of recieving 2nd varivax patient developed fever (Tm=102) and local urticaria and pain.  Rash involve area around injection site and had streaking down to forearm.  No local erythema, no local induration, no local warmth, no local tenderness at time of exam.  No SOB.  Rash improved slightly with benadryl
Anaphylactic shock; A spontaneous report was received from a consumer who is also a 71-year-old female patient who received Moderna's COVID-19 vaccine (mRNA-1273) and experienced anaphylaxis.  The patient's medical history was not included. Products known to have been used by the patient were not provided.  On 27 Jan 2021, prior to the onset of the events, the patient received the first of two planned doses of mRNA-1273 (Lot number: 029L20A) intramuscularly for prophylaxis of COVID-19 infection.    On 27 Jan 2021, after the mRNA-1273 vaccine was being given, the patient noted anaphylaxis symptoms, was rushed to the hospital and hospitalized for 24 hours.  Treatment information included hospitalization, epinephrine and breathing treatments.   Action taken with mRNA-1273 will be discussed with her physician.  The outcome of the event anaphylaxis was unknown.; Reporter's Comments: This case concerns a 71-year-old female patient. The medical history is not provided. The patient experienced a serious unexpected event of Anaphylactic reaction on the same day after receiving their first of two planned doses of mRNA-1273 (Lot # 029L20A). Treatment included epinephrine and breathing treatments. Based on the current available information and temporal association between the use of the product and the onset of the event, a causal relationship cannot be excluded and the event is considered possibly related to the vaccine.
Left leg  with edema, unable to bend Holman Sign (-)  R =46          Left 46 R= 40          L=41 R=36               36  Difficulty in walking 4/16  #21= 4/16 Doctor or other health care professional office clinic visit